Immunocore Ltd has appointed Brian Di Donato as chief financial officer and head of strategy as its lead cancer compound enters pivotal clinical studies. Mr Di Donato was previously CFO at Achillion Pharmaceuticals Inc, a rare disease drug developer which was recently acquired by Alexion Pharmaceuticals Inc. Before that, he held executive positions at several financial firms including Sorin Capital Management and Capmark Investments.
Mr Di Donato holds a master of business administration degree as well as bachelor of science degrees in biology and mechanical engineering.
Immunocore announced the appointment on 6 March 2020.
Copyright 2020 Evernow Publishing Ltd.